MXThe U.S. Food and Drug Administration (FDA) has approved a new flu vaccine called mFlusiva, developed using mRNA technology similar to that used in新冠 vaccines. The vaccine targets adults aged 50 and older, offering potential benefits due to its faster production process compared to traditional flu vaccines. Moderna reported results from a study involving 40,000 participants showing a 27% reduction in flu cases with mFlusiva compared to another brand. For those aged 65 and above, the FDA granted accelerated approval based on smaller trials showing strong immune responses, though additional studies are ongoing. The approval followed a controversial initial rejection by an FDA official, which was later reversed after Moderna challenged the decision.
Bias read (Center): The article presents factual information about the FDA's approval process for a new flu vaccine, including scientific data and regulatory decisions. While there is mention of political figures like Robert F. Kennedy Jr., the focus remains on the medical and regulatory aspects rather than overtly pro
